Staying Independent: How Anesthesia Groups Can Build Leverage Without Selling to a Consolidator
Independent anesthesia groups are being squeezed from more directions than usual right now. Medicare reimbursement continues to tighten, hospitals routinely put coverage contracts out to competitive bid, and private equity-backed management companies keep pursuing acquisitions with a straightforward pitch: sell to us, and you'll get the scale and negotiating power you can't build on your own.
But recent events suggest that pitch deserves more scrutiny than it used to get — and that staying independent doesn't have to mean staying small and powerless. Models like Independent Practice Associations (IPAs) offer a real middle path.
Why "Just Sell to a Consolidator" Looks Less Simple Than It Used To
The roll-up model — where a private equity-backed platform acquires independent anesthesia groups across a state or region to build scale — has been under real regulatory pressure. The Federal Trade Commission sued U.S. Anesthesia Partners (USAP) and its private equity backer, Welsh, Carson, Anderson & Stowe, in 2023, alleging that a decade-long acquisition strategy had consolidated most of the large anesthesia practices in Texas and used the resulting market power to push prices well above competitive levels. In April 2026, the FTC and USAP announced an agreement in principle to settle the case, with the litigation stayed while the parties finalize the terms; the settlement still requires court and Commission approval, and USAP has maintained it operated responsibly and denies the allegations. A separate, private class-action lawsuit from Texas patients alleging overcharges is continuing independently of the settlement.
None of that means every consolidation deal is legally risky, or that every management company operates the way USAP was alleged to. But it's a clear, current example of the kind of regulatory and reputational exposure that can come with the "build market power through acquisition" playbook — exposure that independent groups considering a sale should factor into how they think about their options, and that makes alternative paths to leverage worth a serious look.
Why Independent Groups Still Need Scale-Like Leverage
Staying independent without building any collective leverage isn't a great alternative either. Medicare's anesthesia conversion factor is under continued downward pressure, hospitals actively solicit competing bids for coverage contracts, and payer negotiations increasingly favor whichever side has better data and a stronger market position. A single small group negotiating alone, with no shared data, infrastructure, or negotiating support, is often at a real disadvantage against both larger provider groups and increasingly sophisticated payers.
The goal, then, isn't to avoid scale — it's to find ways to access scale-like advantages without giving up ownership and clinical autonomy.
The IPA Model: What It Is and How It Helps
An Independent Practice Association (IPA) is a legal entity that allows separately owned, independent practices to come together for specific shared purposes — most commonly, contracting support, shared administrative infrastructure, and data aggregation — without merging ownership or clinical operations. Each member group remains independently owned; the IPA exists as a vehicle for the things that genuinely benefit from scale.
For anesthesia groups, an IPA structure can offer:
Aggregated data and benchmarking across member groups, giving everyone better visibility into market rates than any single group could gather alone
Shared administrative infrastructure — potentially including RCM, credentialing support, and compliance resources — spreading fixed costs across a larger base
A stronger presence with hospitals and payers, since a coordinated group of independent practices can represent meaningful combined volume in a given market
Retained autonomy, since each group keeps its own ownership, governance, and clinical decision-making
The Antitrust Line You Need to Respect
Here's the part that requires real legal care: independent practices that compete with one another can't simply agree jointly on the prices they'll charge payers. That kind of direct, unstructured price coordination among competitors raises serious antitrust concerns under federal law — a different legal theory than the market-power concerns raised in the USAP case, but just as real.
To build joint negotiating leverage lawfully, IPAs generally need to operate under one of a few recognized structures:
Clinical integration — the IPA demonstrates real, active coordination of patient care across members (shared protocols, quality initiatives, care coordination programs), which can support joint contracting because the entity is doing more than just setting prices together
Financial risk-sharing — members share meaningful financial risk (such as through capitated or risk-based contracts), which changes the antitrust analysis
A proper "messenger model" — a neutral third party relays individual practices' contract terms to payers without facilitating direct joint price agreement among competitors
None of this is a do-it-yourself project. Any group considering an IPA, clinically integrated network, or similar joint structure should get experienced healthcare antitrust counsel involved from the start — the difference between a lawful, effective structure and an antitrust problem often comes down to details in governance and operations that aren't obvious from the outside.
Other Models Worth Considering
An IPA isn't the only structure available. Depending on a group's goals, a few other models are worth understanding:
Clinically Integrated Networks (CINs) — similar to IPAs but built explicitly around demonstrable care coordination and quality programs, which can support broader joint contracting activity when properly structured
Physician-owned Management Services Organizations (MSOs) — a shared administrative backbone (billing, credentialing, HR, compliance, technology) that member groups own and control jointly, without transferring equity to an outside investor. This is a meaningful contrast to PE-backed MSOs, where scale typically comes bundled with an ownership stake going to the investor
Regional group alliances — even informal, non-contracting alliances focused purely on data-sharing and best practices can help independent groups negotiate from a more informed position, without the legal complexity of a formal joint-contracting entity
Building Leverage Even Without a Formal Structure
Not every group is ready for the investment and governance work an IPA or CIN requires. In the meantime, independent groups can still strengthen their position by:
Investing in real benchmarking data on conversion factors, stipend levels, and payer mix, so every negotiation starts from an informed position rather than a guess
Treating hospital and payer relationships as ongoing, not annual events — starting renewal conversations early and maintaining relationships between negotiation cycles
Partnering with a strong RCM provider that can deliver much of the administrative scale, technology, and negotiating support groups often assume they can only get by selling. A lot of the operational case for joining a consolidator is really an argument for better back-office infrastructure — and that's something an independent group can access through a partnership rather than an ownership sale.
Where Ebility Fits In
Setting up an IPA, CIN, or physician-owned MSO involves more than legal structuring — it also requires the operational backbone to actually make shared scale work in practice. This is where a full-service RCM partner can play a meaningful supporting role:
Shared data and benchmarking infrastructure. Aggregating billing, collections, and payer performance data across member groups is exactly the kind of foundation an IPA or CIN needs to negotiate from a position of real market visibility — and it's core to what an RCM partner already does.
A common administrative backbone. Standardizing billing, credentialing, and reporting processes across independently owned groups is often the hardest practical step in getting a joint structure off the ground. A single RCM partner working across all member groups can make that transition far smoother than each practice maintaining its own separate systems.
Documentation to support clinical integration. Structures that rely on a clinical integration defense need real, demonstrable coordination — consistent quality metrics and reporting across member groups helps build and document that case over time.
Coordination alongside legal counsel, not in place of it. Ebility isn't a law firm and doesn't provide legal advice, but a partner already embedded in each group's billing and data operations can help translate the structure your attorneys design into an actual working system — and help member groups get there together rather than each figuring it out independently.
For groups exploring whether an IPA or similar model makes sense, that operational groundwork is often the difference between a structure that works on paper and one that actually functions day to day.
Final Thoughts
The choice for independent anesthesia groups was never really "stay small and struggle" versus "sell and lose autonomy." Models like IPAs, clinically integrated networks, and physician-owned MSOs offer a legitimate middle path — real negotiating leverage and shared infrastructure, without giving up ownership. Given the regulatory scrutiny recent roll-up deals have faced, that middle path is worth serious consideration, but it has to be built carefully, with real legal guidance, to work as intended.
Ebility.io provides full-service RCM support for independent anesthesia groups — including billing, credentialing, contract negotiation, and the shared data and administrative infrastructure that can help groups explore and build out IPA, CIN, or MSO structures while staying independent. Learn more about our services.
This post is intended for general informational purposes and does not constitute legal advice. Any group considering an IPA, CIN, or similar joint structure should consult experienced healthcare antitrust counsel.